Efficacy of Etoricoxib 60 mg in Modifying Pain Hypersensitivity in People With Knee Osteoarthritis
CompletedPhase 4NCT00927004
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study aims to better understand the way in which painful osteoarthritis affects different people and whether an anti-inflammatory medication such as Arcoxia (etoricoxib) can help to modify this pain. The study will use questionnaires and tests of pain sensitivity to identify arthritis sufferers with more widespread, nerve-type pain and then to investigate whether a daily dose of Arcoxia is more effective than a placebo pill in reducing these symptoms and improving functional movements. The study will also be comparing the same test results of a small group of subjects without knee pain.
Study details
- Official title
- A Randomised Placebo-controlled Trail of Mechanical and Cold Hyperalgesia in Subjects With Painful Knee Osteoarthritis, Compared With Matched Controls, & Whether This Hyperalgesia Can be Modified by a 2-week Course of Etoricoxib 60mg.
- Conditions
- Interventions
- Drug: Etoricoxib (Arcoxia)
- Drug: Sugar pill
- Sponsor
- Curtin University
- Collaborators
- Merck Sharp & Dohme LLC
- Start date
- 2010-08
- Primary completion
- 2011-11
- Sex
- All
- Age range
- from 50 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- Australia
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * unilateral diagnosis of Knee OA \> 6 months * knee pain \> 4/10 on WOMAC pain subscale * if pain in contralateral knee, no greater than "mild" * no other significant joint involvement * ARA functional Class I, II or III * no arthroscopy or injections into index knee in last 6 months Exclusion Criteria: * history of systemic inflammatory or chronic pain disorders (especially fibromyalgia) * neurological deficit * recent (\< 6 months) lower limb surgery * allergic reaction to NSAIDs or aspirin * skin allergies, dermatitis * contraindications to Cox-2 inhibitors: * congestive heart failure (NYHA II-IV) * unstable hypertension * ischaemic heart disease * peripheral artery disease * cerebrovascular disease including CABG or angioplasty within 1 year * severe hepatic dysfunction * active GI bleeding or peptic ulceration * reduced creatinine clearance \< 30 mL/min * current use of high dose (\> 325 mg daily) aspirin
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00927004